嵌入式工程益生菌的协同治疗效率 嵌入式自组装氨酸水凝用于性结肠炎治疗
Yijiao Wen1, Chunhua Zhang1, Xuanting Wang1
1Green Pharmaceutical Technology Key Laboratory of Luzhou, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
ACS applied bio materials
|November 12, 2025
概括
研究人员用羽毛废物制造了酸水凝,以口服提供益生菌. 这种方法提高了益生菌在治疗大肠炎中的生存率和疗效,为活生物疗法提供了一个新的平台.
科学领域:
- 生物材料科学 生物材料科学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 益生菌的口服和活力面临临临床使用的重大挑战.
- 活生物疗法需要有效的输送系统来增强胃肠道耐受性和生物可用性.
研究的目的:
- 开发一种具有成本效益和可扩展的方法,用于使用氨酸水凝进行益生菌封装.
- 为了设计益生菌在肠道的特定部位释放.
- 在大肠炎小鼠模型中评估封装益生菌的治疗疗效.
主要方法:
- 从羽毛废物中通过二硫化物混合合成了氨酸水凝.
- 封装了多种益生菌菌株,包括*大肠杆菌*尼斯尔1917 (EcN).
- EcN被设计为表达氨酶 (EcNker) 进行向的水凝降解.
- 治疗疗效被评估在硫酸诱导的大肠炎小鼠模型中.
主要成果:
- 氨酸水凝显著改善了益生菌的胃肠道耐受性和口服生物可用性.
- 与未封装益生菌相比,凝封装的EcNker在大肠炎小鼠中表现出更好的治疗效果.
- 治疗恢复了结肠组织学,减少了细胞灭绝,正常化了细胞因子配置,增强了肠道屏障完整性,调节了微生物群,增加了短链脂肪酸.
结论:
- 氨酸水凝代表了一种有前途的生物相容平台,用于口服输送工程益生菌.
- 这种方法提高了治疗结肠炎和潜在的其他疾病的益生菌疗效.
- 来自羽毛的氨酸水凝为活体生物治疗提供了可持续和可扩展的解决方案.
相关概念视频
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
01:26Peptic Ulcer Disease IV: Management
419
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
419
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
01:28Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K